Skip to content
Back Home
  • Home
  • Scientific Platforms
  • Team
  • Contact Us
Back Home
  • Search
  • Home
  • Scientific Platforms
  • Team
  • Contact Us
Home » Uncategorized » Manhattan BioSolutions secures non-dilutive angel funding
Uncategorized

Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

You may also like

Published September 1, 2018

Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball= Project Number: 1R43CA228746-01A1 Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER

Published August 26, 2020

EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies

New York, NY August 25, 2020—EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a strategic research collaboration with […]

Published June 1, 2022

Manhattan BioSolutions Enters into a Research Collaboration And License Option Agreement with Binghamton University for the New Linker-Payload Technology

https://www.accesswire.com/703518/Manhattan-BioSolutions-Enters-into-a-Research-Collaboration-And-License-Option-Agreement-with-Binghamton-University-for-the-New-Linker-Payload-Technology NEW YORK, NY / ACCESSWIRE / June 1, 2022 / Manhattan BioSolutions, Inc., an emerging biotechnology company developing new classes of therapeutic […]

Published August 12, 2022

Manhattan BioSolutions, Inc. Signs Commercial Evaluation License Agreements with the National Institutes of Health (NIH) for Use of Monoclonal Antibodies in Novel Antibody-Drug Conjugate (ADC) Oncology Programs

https://www.accesswire.com/709117/Manhattan-BioSolutions-Inc-Signs-Commercial-Evaluation-License-Agreements-with-the-National-Institutes-of-Health-NIH-for-Use-of-Monoclonal-Antibodies-in-Novel-Antibody-Drug-Conjugate-ADC-Oncology-Programs NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. today announced it has entered into two commercial evaluation […]

Post navigation

  • Back to post list
  • Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University

© 2023 Manhattan BioSolutions – All rights reserved

Powered by WP – Designed with the Customizr theme